20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Viking Therapeutics Inc (VKTX) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 65 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, VKTX reported $0M in revenue and ($360M) in net income.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — |
| Gross Margin % | — | — | — | — | — | -2766.1% | 100.0% | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($560M) | ($393M) | ($151M) | ($101M) | ($70M) | ($56M) | ($43M) | ($33M) | ($26M) | ($19M) | ($14M) | ($12M) | ($23M) | $0M | $0M |
| Operating Margin % | — | — | — | — | — | -520343.9% | -397558.5% | — | — | — | — | — | — | — | — |
| Net Income | ($535M) | ($360M) | ($110M) | ($86M) | ($69M) | ($55M) | ($39M) | ($26M) | ($22M) | ($21M) | ($15M) | ($23M) | ($22M) | $0M | $0M |
| Net Margin % | — | — | — | — | — | -513877.2% | -368045.9% | — | — | — | — | — | — | — | — |
| EBITDA | ($534M) | ($359M) | ($110M) | ($101M) | ($69M) | ($55M) | $4M | ($25M) | $5M | $0M | $1M | ($21M) | ($21M) | $0M | $0M |
| Earnings Per Share (EPS) | $-4.67 | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | $-0.54 | $-0.36 | $-0.38 | $-0.79 | $-0.90 | $-3.68 | $-5.08 | $-0.03 | $-0.30 |
| Shares Outstanding (M) | 116M | 113M | 109M | 94M | 77M | 77M | 73M | 72M | 58M | 26M | 16M | 6M | 4M | 4M | 0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | $0M | $0M | $0M | — | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($133M) | ($164M) | ($165M) | ($99M) | ($75M) | ($55M) | ($46M) | ($37M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($128M) | ($158M) | ($158M) | ($91M) | ($66M) | ($46M) | ($35M) | ($25M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($128M) | ($158M) | ($158M) | ($91M) | ($65M) | ($45M) | ($35M) | ($25M) |
| Earnings Per Share (EPS) | $-1.10 | $-1.37 | $-1.38 | $-0.81 | $-0.58 | $-0.41 | $-0.32 | $-0.22 |
| Shares Outstanding (M) | 116M | 116M | 114M | 112M | 112M | 112M | 111M | 111M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($418M) | ($279M) | ($88M) | ($73M) | ($48M) | ($48M) | ($22M) | ($25M) | ($19M) | ($15M) | ($11M) | ($9M) | ($2M) | $0M | $0M |
| Free Cash Flow (FCF) | ($418M) | ($279M) | ($88M) | ($73M) | ($48M) | ($48M) | ($22M) | ($25M) | ($19M) | ($15M) | ($11M) | ($9M) | ($2M) | $0M | $0M |
| FCF Margin % | — | — | — | — | — | -444687.4% | -202935.4% | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | $0M | $0M | $0M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($125M) | ($114M) | ($85M) | ($94M) | ($47M) | ($52M) | ($31M) | ($22M) |
| Free Cash Flow (FCF) | ($125M) | ($114M) | ($85M) | ($94M) | ($47M) | ($52M) | ($31M) | ($22M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $522M | $716M | $908M | $368M | $169M | $211M | $257M | $284M | $302M | $22M | $15M | $15M | $3M | $0M | — |
| Cash & Cash Equivalents | $126M | $166M | $27M | $56M | $37M | $26M | $29M | $8M | $25M | $9M | $3M | $1M | $1M | $0M | — |
| Total Liabilities | $114M | $77M | $28M | $20M | $23M | $9M | $12M | $7M | $5M | $9M | $6M | $7M | $25M | $0M | $0M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $3M | $3M | $4M | $2M | $0M | $0M |
| Total Shareholders' Equity | $408M | $639M | $880M | $348M | $145M | $202M | $244M | $277M | $298M | $13M | $8M | $9M | ($22M) | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VKTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms